Hinsch Gylvin Lykke 4/A

What Happened Hinsch Gylvin Lykke, a director of ProQR Therapeutics N.V. (PRQR), received a grant of derivative awards covering 14,595 shares on June 2, 2026. The Form 4/A reports the acquisition price as $0.00 (award/derivative); a footnote explains the reported price basis is the issuer’s closing market price on June 1, 2026 per the Board Compensation Policy. This is a grant of options (not a cash purchase or sale) and does not represent an immediate sale.

Key Details

• Transaction type: Award/Grant of derivative security (options) to a director.
• Transaction date: June 2, 2026 (reported on an amended Form 4/A filed June 30, 2026).
• Shares/options granted: 14,595. Reported acquisition price: $0.00 (see footnote).
• Vesting: 25% vests and becomes exercisable on June 2, 2027; remaining 75% vests in 12 substantially equal quarterly installments thereafter, subject to continued service (footnote).
• Amendment: This Form 4/A corrects the number of share options reported in the original Form 4 filed June 3, 2026; no other changes.
• Shares owned after transaction: Not specified in the provided filing summary.
• Timeliness: Original Form 4 was filed June 3 (timely); this is an amendment to correct quantity.

Context This is a standard equity-compensation grant to a director. Because these are options subject to vesting, they represent potential future shares contingent on continued service and vesting dates—not an immediate inflow or sale. Such grants are routine for board compensation and should be interpreted as long-term incentive awards rather than near-term trading activity.